Quantifying Artificial Pancreas-related Changes in Diabetic Neuropathy (QUANT-AP)
Diabetes Complications, Diabetes Mellitus, Type 1, Diabetic Neuropathies
About this trial
This is an interventional treatment trial for Diabetes Complications focused on measuring Diabetes
Eligibility Criteria
Inclusion Criteria: Type 1 diabetes aged 18-70 who falls into either of these three categories and has the ability to read and comprehend English: Starting Artificial Pancreas therapy as determined for clinical need Starting insulin pump therapy as determined for clinical need On multiple daily injection therapy for insulin delivery Exclusion Criteria: History of ocular disease that may affect the cornea. History of corneal trauma or surgery (NB cataract surgery does not preclude enrolment unless surgery occurred in the 3 months prior to enrolment date) Concurrent ocular disease, infection or inflammation. History of neuropathy due to alcoholism, renal impairment requiring renal replacement therapy, infectious disease (e.g., Lyme disease, HIV/AIDS, hepatitis B), liver failure, B12 deficiency Unable to read and comprehend English
Sites / Locations
- Manchester Diabetes Centre, Manchester University NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
MDI
Artificial Pancreas - Closed Loop
All participants will have: Continuous Glucose Monitoring Neuropathy Assessments and Pain Questionnaires ACR, Blood Tests
All participants will have: Continuous Glucose Monitoring Neuropathy Assessments and Pain Questionnaires ACR, Blood Tests